Home/Pipeline/Taiho Oncology Pipeline

Taiho Oncology Pipeline

Various solid tumors

Multiple (I-III)ActiveN/A

Key Facts

Indication

Various solid tumors

Phase

Multiple (I-III)

Status

Active

Company

Otsuka Holdings

About Otsuka Holdings

Otsuka Holdings is a multinational healthcare leader founded on the mission 'Otsuka-people creating new products for better health worldwide.' It has achieved global prominence through flagship CNS drugs, a strategic stake in Lundbeck, and blockbuster nutraceutical brands like Pocari Sweat. The company's strategy is built on a diversified four-pillar business model—pharmaceuticals, nutraceuticals, medical devices, and chemicals—driven by a unique culture of creativity ('Souzoususei') and evidence-based validation ('Jisshou').

View full company profile

Therapeutic Areas

Central Nervous System Psychiatry Neurology Oncology Nephrology Cardiovascular

Other Various solid tumors Drugs

Drug	Company	Phase	Status
NUC-8232	NuCana	Phase 1	Active
TCR Library Program	Medigene	Discovery	Active
Solid Tumor Profiling	Diatech Pharmacogenetics	Commercial	Active
BAVENCIO (avelumab)	EMD Serono	Approved	Active (Lifecycle Management)
Jemperli (dostarlimab) combinations	GSK	Phase 3	Active
FoundationOne®CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
FoundationOne®Liquid CDx Indication Expansion	Foundation Medicine	Approved/Commercial	Active
Lenvatinib + Pembrolizumab	Eisai	Phase 3 / Marketed	Active (label expansions)
PD-1/PD-L1 Inhibitor	PeptiDream	Phase 1	Active
Cadonilimab (AK104)	Akeso	Phase III	Active
TEVIMBRA (tislelizumab)	BeOne Medicines	Approved / Phase 3	Commercial / Late-stage Development
Early I-O Pipeline	Ipsen	Pre-clinical / Phase 1	Active early development